Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual M ...Middle East

SAN FRANCISCO and SUZHOU, China, June 2, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune,...

Hence then, the article about innovent delivers oral presentation of clinical data of a randomized controlled phase 1b study evaluating ibi310 anti ctla 4 monoclonal antibody in combination with sintilimab as neoadjuvant treatment of colon cancer at 2024 asco annual m was published today ( Monday 03/06/2024 - 04:49 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual M )

Also on site :

• Saudi Arabia to unify LPG gas cylinder prices nationwide from January 2026
• 2 found dead after family disturbance reported in Concord
• Two dozen killed in Ukrainian strike on Russian New Year’s celebration – governor